ISSN: 2161-0460

Revista de enfermedad de Alzheimer y parkinsonismo

Acceso abierto

Nuestro grupo organiza más de 3000 Series de conferencias Eventos cada año en EE. UU., Europa y América. Asia con el apoyo de 1.000 sociedades científicas más y publica más de 700 Acceso abierto Revistas que contienen más de 50.000 personalidades eminentes, científicos de renombre como miembros del consejo editorial.

Revistas de acceso abierto que ganan más lectores y citas
700 revistas y 15 000 000 de lectores Cada revista obtiene más de 25 000 lectores

Indexado en
  • Índice Copérnico
  • Google Académico
  • sherpa romeo
  • Abrir puerta J
  • Revista GenámicaBuscar
  • Claves Académicas
  • TOC de revistas
  • Infraestructura Nacional del Conocimiento de China (CNKI)
  • Biblioteca de revistas electrónicas
  • Búsqueda de referencia
  • Universidad Hamdard
  • EBSCO AZ
  • OCLC-WorldCat
  • Catálogo en línea SWB
  • Biblioteca Virtual de Biología (vifabio)
  • publones
  • Fundación de Ginebra para la educación y la investigación médicas
  • Pub Europeo
  • ICMJE
Comparte esta página

Abstracto

Lifetime Expectancy in Dementia with Lewy Bodies: Effects of Donepezil Administration and Special Nursing Home Replacement. A Retrospective Analysis in the Tajiri Project

Kenichi Meguro, Keiichi Kumai, Junko Takada, Keiko Chida, Yuriko Kato and Satoshi Yamaguchi

Objective: Cholinesterase inhibitors (ChEIs) can delay the progression of Alzheimer disease (AD). We previously demonstrated a positive effect of donepezil (DNP) administration and a Special Nursing Home (SNH) replacement on lifetime expectancy after the onset of AD. Recently DNP has been indicated for use in the treatment of dementia with Lewy Bodies (DLB); however, the effect on lifetime expectancy remains unclear. Herein, we analyzed the effects of DNP on DLB.

Methods: All outpatients at the Tajiri Clinic with available medical records and death certificates from 1999- 2012 were included in this retrospective analysis. The entry criteria were a diagnosis of dementia based on DSM-IV criteria and diagnosis of DLB using the international consensus criteria; medical treatment for more than 3 months and follow up to less than 1 year before death.

Results: We identified 510 subjects based upon medical records and death certificates, of which 360 had a diagnosis of dementia that met the entry criteria. Of 51 patients diagnosed with DLB, 23 had taken DNP and 28 patients had not undergone drug treatment due to treatment prior to the introduction of DNP in 1999 in Japan. The lifetime expectancies after onset were 6.4 years in the DNP group and 3.6 years in the non-DNP group; with a significant drug effect. However, in contrast with the previous AD data, no significant effect of SNH residency was noted.

Conclusion: Although this report has the limitation that all analyses were retrospective and lacked randomization, we found a positive effect of DNP on lifetime expectancy after the onset of DLB. The lower life expectancy compared with that of AD and the lack of an effect of SNH residency suggest the cholinergic deficiency in DLB is greater than that in AD.